The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 243K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pike, S. E.
Right arrow Articles by Tosato, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pike, S. E.
Right arrow Articles by Tosato, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1998/12/2349/ $5.00
The Journal of Experimental Medicine, Volume 188, Number 12, December 21, 1998 2349-2356

Articles

Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth

Sandra E. Pike*, Lei Yao*, Karen D. Jones*, Barry Cherney*, Ettore Appella{ddagger}, Kazuyasu Sakaguchi{ddagger}, Hira Nakhasi*, Julie Teruya-Feldstein§, Peter Wirth||, Ghanshyam Gupta*, and Giovanna Tosato*

From the * Center for Biologics Evaluation and Research, Rockville, Maryland 20852; and the {ddagger} Laboratory of Cell Biology, the § Laboratory of Pathology, and the || Laboratory of Experimental Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892

An endothelial cell inhibitor was purified from supernatant of an Epstein-Barr virus–immortalized cell line and identified as fragments of calreticulin. The purified recombinant NH2-terminal domain of calreticulin (amino acids 1–180) inhibited the proliferation of endothelial cells, but not cells of other lineages, and suppressed angiogenesis in vivo. We have named this NH2-terminal domain of calreticulin vasostatin. When inoculated into athymic mice, vasostatin significantly reduced growth of human Burkitt lymphoma and human colon carcinoma. Compared with other inhibitors of angiogenesis, vasostatin is a small, soluble, and stable molecule that is easy to produce and deliver. As an angiogenesis inhibitor that specifically targets proliferating endothelial cells, vasostatin has a unique potential for cancer treatment.

Key Words: endothelial cells • angiogenesis • cell growth • cancer • antitumor agent

Address correspondence to Giovanna Tosato, Center for Biologics Evaluation and Research, Building 29A, Room 2D16, HFM535, 1401 Rockville Pike, Rockville, MD 20852-1448. Phone: 301-827-1794; Fax: 301-480-3256; E-mail: Tosato{at}A1.CBER.FDA.GOV

S.E. Pike and L. Yao contributed equally to this work.

Abbreviations used: aa, amino acids; bFGF, basic fibroblast growth factor; FBHE, fetal bovine heart endothelial cells; HUVEC, human umbilical vein endothelial cells; IP-10, IFN-{gamma} inducible protein-10; MBP, maltose-binding protein; Mig, monokine induced by IFN-{gamma}; VEGF, vascular endothelial growth factor.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS